title: ESAs further restricted, but debate continues.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D000740:Anemia / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068256:Darbepoetin alfa; D004348:Drug Labeling; D011307:Drug Prescriptions / Q000592:standards; D000068817:Epoetin Alfa; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives; D005060:Europe; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced* / Q000188:drug therapy; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa